» Articles » PMID: 26022569

Vaccines: from Valuation to Resource Allocation

Overview
Journal Vaccine
Date 2015 May 30
PMID 26022569
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

This review focuses on selected challenges and opportunities concerning broader valuation of vaccines and immunization. The challenges involve conceptualizing and measuring the value of vaccines, while the opportunities relate to the strategic and systematic use of that information in health policy decisions that range from the adoption of particular vaccines in national immunization plans to the allocation of resources to vaccine research, development, and delivery. Clarifying the demonstrable individual, family, and community-level benefits of vaccines will allow the public health community to make better-informed and more meaningful comparisons of the costs of vaccines in relation to their full benefits. Taking advantage of this opportunity will require enhanced data collection and the development of strategic planning tools for transparently assessing trade-offs among the myriad attributes of different vaccines in various social and economic contexts.

Citing Articles

Determinants of basic childhood vaccination coverage in European and OECD countries.

Varbanova V, Verelst F, Hens N, Beutels P Hum Vaccin Immunother. 2022; 18(6):2123883.

PMID: 36173818 PMC: 9746410. DOI: 10.1080/21645515.2022.2123883.


Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/inflammatory syndrome expand?.

Jara L, Vera-Lastra O, Mahroum N, Pineda C, Shoenfeld Y Clin Rheumatol. 2022; 41(5):1603-1609.

PMID: 35378658 PMC: 8979721. DOI: 10.1007/s10067-022-06149-4.


Advancing sustainable development goals through immunization: a literature review.

Decouttere C, De Boeck K, Vandaele N Global Health. 2021; 17(1):95.

PMID: 34446050 PMC: 8390056. DOI: 10.1186/s12992-021-00745-w.


National decision-making for the introduction of new vaccines: A systematic review, 2010-2020.

Donadel M, Panero M, Ametewee L, Shefer A Vaccine. 2021; 39(14):1897-1909.

PMID: 33750592 PMC: 10370349. DOI: 10.1016/j.vaccine.2021.02.059.


Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits.

Stawasz A, Huang L, Kirby P, Bloom D Front Public Health. 2020; 8:261.

PMID: 32754566 PMC: 7366491. DOI: 10.3389/fpubh.2020.00261.